|
市場調查報告書
對於癌症治療個別化的分子診斷之進展
Advancing Molecular Diagnostics to Personalize Cancer Therapy
|
對於癌症治療個別化的分子診斷之進展 是由出版商Business Insights在2011年06月所出版的。
這份英文市場調查報告書包含Pages: 187 價格從美金3835起跳。
基因組學、蛋白質組學、分子圖像等新技術的進歩連結了惡性疾病分子的再分類，創造了診斷藥製造商的市場的機會。
本報告書為癌症分子診斷市場的現狀與將來的動向的分析、2016年為止的成長預測、乳癌、前立腺癌等各領域市場動向、研究方向性與業界面臨的課題等整理，概述如下。
總綱
導論
- 摘要
- 前景
- 分子標的療法
- 對於個別化癌治療的戰略
- 短期的市場機會
- 藥劑・診斷共同開發
癌症診斷動向
- 摘要
- 科學的發展
- 醫療的發展
- 上市時間縮短
- 對法規體制問題的對應
- 臨床行為的變化
- 診斷對治療用分子發現之影響
- 主要平台
- 生物標記的作用
- 課題與問題
- 診斷的商品化
- 法規體制上的課題
- 技術上的課題
- DTC與CTC
市場發展
- 摘要
- 對子宮頸癌的新分子檢査
- EGFR肺癌檢査認證
- 為了前列腺癌生物標記的擴充認證契約
- BioMerieux、GSP為了治療的選擇而開發診斷方法
- 胰臓癌的診斷檢査
- 皮膚癌免疫療法的候補選定檢査
- 併用診斷
- 新癌診工具開發促進契約
- 癌證放射線治療個別化用生物標記
- 晶片追蹤中對皮膚瘤的CTC抗體
- 透過體液的癌診斷
- 針對惡性黑色素瘤的受到妥當性確認的基因標記
- 黑色素瘤組織的DNA甲基化生物標記
- 前立腺癌再發預測診斷
- 受承認的結腸直腸癌檢査
市場分析
- 摘要
- 市場促進因子
- 市場的機會
- 市場的新規產品
- 世界市場分析
企業簡介
圖表
Abstract
Introduction
This report analyzes current and potential world markets for key cancer-based
molecular diagnostics, including advances in the field. This report forecasts
future growth to 2016. Market segments covered include: breast cancer; colon
cancer; prostate cancer; non-small cell lung cancer; melanoma; and renal
cancer. This report reviews the direction of research, and key issues facing
the industry.
Features and benefits
- Identify key innovations in molecular diagnostics for oncology that may
compete with those in development at your company.
- Understand the regulatory challenges facing the developers of molecular
diagnostics for cancer.
- Understand the challenges that surround successfully commercializing a
combined drug-diagnostic product and learn how to overcome them.
- Discover and analyze the key technology platforms being used in the
development of novel molecular diagnostics.
- Discover the forecast market size for key segments of the cancer
diagnostics market including: breast, colorectal, prostate, lung, and renal
cancer.
Highlights
Advances in genomics, proteomics, molecular imaging, and other new
technologies are leading to a molecularly based reclassification of
malignancy, creating market opportunities for diagnostic companies.
Companion diagnostics - linking drugs with diagnostics - is expected to become
the prevailing health care model, offering advantages for both the
prescription drug and diagnostics businesses. For diagnostics companies,
combining with a successful companion drug can be a powerful driver of sales,
especially when required for prescribing a drug.
If government regulatory agencies increase the use of biomarkers and
diagnostics in prescribing decisions, it is likely that drug and diagnostics
companies will increase their collaboration. New relationships are likely to
develop between partners committed to personalized medicine embracing the
approach of specialized pharmaceutical firms.
Your key questions answered
- Which of the cancer diagnostic market segments are forecast to grow most
rapidly through to 2016 and thus be the most commercially attractive?
- What are the key innovations in molecular diagnostics that are going to
drive market growth?
- How can pharma and diagnostic companies work together to successfully
develop combined drug and diagnostic products?
- Which companies are developing the most promising technologies?
Table of Contents
About the author
EXECUTIVE SUMMARY
- Introduction
- Trends in cancer diagnostics
- Market developments
- Market analysis
Introduction
- Perspective
- Growing global incidence of cancer
- The impact of unhealthy lifestyles on cancer
- Personalized therapy gets closer
- Molecularly targeted therapeutics
- Move toward rationally designed trials
- Accelerate the translation of preclinical research
- Strategies toward personal cancer treatment
- Near-term market opportunities
- New pharmacogenomics, panels and arrays
- Driving demand for tests
- Drug-diagnostic co-development
- Targeted drugs fueling diagnostic growth
- Stratifying patients to the best treatment
Trends in cancer diagnostics
- Evolving health care practices
- Reducing time to market
- Addressing regulatory concerns
- Changing clinical practice
- Diagnostic influences therapeutic molecule discovery
- Identifying patient populations
- Key platforms
- PCR
- Nucleic acid testing
- Microfluidics
- Gene expression profiling
- Variety
- The role of biomarkers
- Prognostic
- Predictive
- Evaluating therapeutic activity
- Challenges and issues
- Commercializing theranostics
- Regulatory challenges
- Technical challenges
- DTCs and CTCs
Market developments
- New molecular test for cervical cancer
- Detecting high risk types of HPV
- License for EGFR lung cancer assay
- Licensing agreement extended for prostate cancer biomarker
- bioMerieux, GSK develop theranostic for treatment selection
- Diagnostic test for pancreatic cancer
- Test to select candidates for skin cancer immunotherapy
- Collaboration for therapy, companion diagnostic
- Companion diagnostics collaboration
- Deal to accelerate development of new cancer diagnosis tools
- Biomarkers for personalizing radiation cancer treatment
- CTC antibodies on a chip track mesothelioma
- Body fluid based oncology diagnostics
- Highly validated genetic markers for malignant melanoma
- Biomarkers for DNA methylation on melanoma tissue
- Diagnostic predicts prostate cancer recurrence
- Colorectal cancer test approved
Market analysis
- Market drivers
- Improving on prescription by trial and error
- A need for more rapid, specific testing
- Opportunities
- Drug-diagnostic combinations
- Rescuing failed drugs
- An unmet need for improving diagnosis
- Selected novel products on the market
- HPV and cervical cancer
- Multigene expression testing
- Predicting risk of recurrence
- Gene overexpression
- KRAS mutations
- Molecular classification
- Mutation analysis
- Drug resistance testing
- Measuring exposure to drugs
- World market analysis
- Total solutions
- Drug labeling modifications
- Breast cancer
- Colorectal cancer
- Prostate cancer
- Non-small cell lung cancer
- Melanoma
- Renal cancer
- Market by type of diagnostic
Corporate Profiles
- Becton, Dickinson and Company
- Roche Molecular Diagnostics
Appendix
- Scope
- Methodology
- Glossary/Abbreviations
- Bibliography/References
TABLES
- Table: Global incidence and mortality of cancer by type, 2008, thousands
- Table: Incidence and mortality of cancer by economic status, 2008,
thousands
- Table: Selected oncology Rx-Dx co-development projects
- Table: Cancer drugs for which testing is recommended/required in the US
- Table: Early players in cancer molecular diagnostics markets
- Table: Selected molecular diagnostics targeting HPV and cervical cancer
- Table: World market for breast cancer molecular diagnostics, 2009-2016,
($m)
- Table: World market for colorectal cancer molecular diagnostics,
2009-2016, ($m)
- Table: World market for prostate cancer molecular diagnostics, 2009-2016,
($m)
- Table: World market for NSCLC molecular diagnostics, 2009-2016, ($m)
- Table: World market for melanoma molecular diagnostics, 2009-2016, ($m)
- Table: World market for renal cancer molecular diagnostics, ($m)
FIGURES
- Figure: Leading male cancers by mortality, global, 2008
- Figure: Leading female cancers by mortality, global, 2008
- Figure: Molecular profiling technologies facilitating personalized medicine
- Figure: Key processes involved in moving research into the clinic
- Figure: Potential of diagnostic-drug combinations
- Figure: Evolution of diagnostics
- Figure: Challenges for cancer molecular diagnostics manufacturers
- Figure: Cancer molecular diagnostics market by type of diagnostic
|
